Beta-2-glycoprotein-1 and alpha-1-antitrypsin as urinary markers of renal cancer in von Hippel–Lindau patients. (17th February 2018)

• Record Type: Journal Article
• Authors: Mandili, Giorgia; Notarpietro, Agata; Khadjavi, Amina; Allasia, Marco; Battaglia, Antonino; Lucatello, Barbara; Frea, Bruno; Turrini, Francesco; Novelli, Francesco; Giribaldi, Giuliana; Destefanis, Paolo
• Is Part Of: Biomarkers. Volume 23:Number 2(2018)
• Page Start: 123
• Page End: 130
• Publication Date: 2018-02-17
• Subjects: Von Hippel–Lindau disease -- renal cancer -- beta-2-glycoprotein-1 and alpha-1-antitrypsin -- urine -- proteomics; Biochemical markers -- Periodicals; 610.28
• DOI: 10.1080/1354750X.2016.1269132
• Languages: English
• ISSNs: 1354-750X

Abstract

Abstract: Context: Von Hippel–Lindau disease (VHLD) is a rare inherited neoplastic syndrome. Among all the VHLD-associated tumors, clear cell renal cell carcinoma (ccRCC) is the major cause of death. Objective: The aim of this paper is the discovery of new non-invasive biomarker for the monitoring of VHLD patients. Materials and methods: We compared the urinary proteome of VHLD patients, ccRCC patients and healthy volunteers. Results: Among all differentially expressed proteins, alpha-1-antitrypsin (A1AT) and APOH (beta-2-glycoprotein-1) are strongly over-abundant only in the urine of VHLD patients with a history of ccRCC. Discussion and conclusion: A1AT and APOH could be promising non-invasive biomarkers.